Processing

Please wait...

Settings

Settings

Goto Application

Offices all Languages Stemming false Single Family Member true Include NPL false
RSS feed can only be generated if you have a WIPO account

Save query

A private query is only visible to you when you are logged-in and can not be used in RSS feeds

Query Tree

Refine Options

Offices
All
Specify the language of your search keywords
Stemming reduces inflected words to their stem or root form.
For example the words fishing, fished,fish, and fisher are reduced to the root word,fish,
so a search for fisher returns all the different variations
Returns only one member of a family of patents
Include Non-Patent literature in results

Full Query

IC:C07D

Side-by-side view shortcuts

General
Go to Search input
CTRL + SHIFT +
Go to Results (selected record)
CTRL + SHIFT +
Go to Detail (selected tab)
CTRL + SHIFT +
Go to Next page
CTRL +
Go to Previous page
CTRL +
Results (First, do 'Go to Results')
Go to Next record / image
/
Go to Previous record / image
/
Scroll Up
Page Up
Scroll Down
Page Down
Scroll to Top
CTRL + Home
Scroll to Bottom
CTRL + End
Detail (First, do 'Go to Detail')
Go to Next tab
Go to Previous tab

Analysis

1.WO/2022/107167BICYCLIC HETEROCYCLIC COMPOUNDS FOR TREATMENT OF TUBERCULOSIS
WO 27.05.2022
Int.Class C07D 471/04
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
471Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/-C07D463/251
02in which the condensed system contains two hetero rings
04Ortho-condensed systems
Appl.No PCT/IN2021/051081 Applicant DR REDDY'S INSTITUTE OF LIFE SCIENCES Inventor REDDY, Gangireddy Sujeevan
The present invention relates to a compound of formula (I): or a pharmaceutically acceptable salt or a stereoisomer thereof, wherein ring A, R1, m and n are same as defined in the specification. The present invention also relates to compositions comprising such compounds, use of such compounds and methods of treating a condition, disease or disorder using such compounds and/or compositions.
2.WO/2022/109057INHIBITION OF GLYCOGEN SYNTHASE KINASE-3 (GSK-3)
WO 27.05.2022
Int.Class A61K 31/404
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
40having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
403condensed with carbocyclic rings, e.g. carbazole
404Indoles, e.g. pindolol
Appl.No PCT/US2021/059771 Applicant BROWN UNIVERSITY Inventor EL-DEIRY, Wafik, S.
The invention provides small-molecule inhibition of GSK-3 to increase efficacy of ICB and improve response in patients with microsatellite stable colorectal cancer, and possibly other tumor types. These results demonstrate 9-ING-41 in combination with αPD-1/PD-L1 therapy.
3.WO/2022/1091173-AMINO PYRROLIDINE AND PIPERIDINE MACROCYCLIC OREXIN RECEPTOR AGONISTS
WO 27.05.2022
Int.Class C07D 273/02
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
273Heterocyclic compounds containing rings having nitrogen and oxygen atoms as the only ring hetero atoms, not provided for by groups C07D261/-C07D271/183
02having two nitrogen atoms and only one oxygen atom
Appl.No PCT/US2021/059862 Applicant MERCK SHARP & DOHME CORP. Inventor BOGEN, Stephane, L.
The present invention is directed to 3-amino pyrrolidine and piperidine macrocyclic compounds which are agonists of orexin receptors. The present invention is also directed to uses of the compounds described herein in the potential treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved. The present invention is also directed to compositions comprising these compounds. The present invention is also directed to uses of these compositions in the potential prevention or treatment of such diseases in which orexin receptors are involved.
4.WO/2022/109492PYRROLOPYRIDAZINE COMPOUNDS AS KINASE INHIBITORS
WO 27.05.2022
Int.Class C07D 487/04
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
487Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/-C07D477/183
02in which the condensed system contains two hetero rings
04Ortho-condensed systems
Appl.No PCT/US2021/060634 Applicant GOSSAMER BIOSERVICES, INC. Inventor MICHELS, Theodore David
Described herein are inhibitors of JAK kinases, pharmaceutical compositions comprising them, processes for preparing them and uses of such inhibitors to treat or prevent diseases, disorders and conditions associated with kinase function.
5.WO/2022/105636SPIRO COMPOUND, PHARMACEUTICAL COMPOSITION CONTAINING SAME, AND USE THEREOF
WO 27.05.2022
Int.Class C07D 401/14
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
401Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
14containing three or more hetero rings
Appl.No PCT/CN2021/129425 Applicant SHANGHAI EUREGEN BIOPHARMA CO., LTD. Inventor CHEN, Xuxing
Disclosed are a spiro compound, a pharmaceutical composition containing same, and the use thereof. The spiro compound interferes with interaction between the protein menin and MLL1, MLL2 or MLL fusion oncoproteins, and is expected to be used for a drug for the treatment of tumors, diabetes and other diseases that depend on the activity of MLL1, MLL2 or MLL fusion proteins, and/or the protein menin.
6.WO/2022/105771NITROGEN-CONTAINING HETEROCYCLIC DERIVATIVE, AND PREPARATION METHOD THEREFOR AND MEDICAL APPLICATION THEREOF
WO 27.05.2022
Int.Class C07D 403/14
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
403Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/167
14containing three or more hetero rings
Appl.No PCT/CN2021/131078 Applicant JIANGSU HENGRUI MEDICINE CO., LTD. Inventor LI, Xin
The present invention relates to a nitrogen-containing heterocyclic derivative, and a preparation method therefor and a medical application thereof. Specifically, the present invention relates to a nitrogen-containing heterocyclic derivative represented by general formula (I), a preparation method therefor, a pharmaceutical composition containing the derivative, and use thereof as a therapeutic agent, in particular the use thereof as a TYK2 inhibitor and in the preparation of a drug for treating and/or preventing inflammatory and autoimmune diseases.
7.WO/2022/105921PYRIMIDO-HETEROCYCLIC COMPOUND, PREPARATION METHOD THEREFOR, AND USE THEREOF
WO 27.05.2022
Int.Class C07D 471/04
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
471Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/-C07D463/251
02in which the condensed system contains two hetero rings
04Ortho-condensed systems
Appl.No PCT/CN2021/132190 Applicant SHANGHAI RINGENE BIOPHARMA INC. Inventor WAN, Huixin
The present invention relates to a class of pyrimido-heterocyclic compounds, a preparation method therefor, and a use thereof. The compound is specifically a pyrimido-fused ring compound represented by general formula I, or a pharmaceutically acceptable salt thereof, or an enantiomer, diastereomer, a tautomer, a twisted isomer, a solvate, a polymorph, or a prodrug thereof, a preparation method therefor, and a pharmaceutical use thereof. The compound can be used as an SOS1 inhibitor in the preparation of a tumor treatment drug.
8.WO/2022/106551CO-CRYSTALS OF A ROR GAMMA INHIBITOR
WO 27.05.2022
Int.Class A61P 37/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
37Drugs for immunological or allergic disorders
Appl.No PCT/EP2021/082162 Applicant BOEHRINGER INGELHEIM INTERNATIONAL GMBH Inventor GAO, Joe, Ju
The present invention relates to co-crystal forms of the following compound (I).
9.WO/2022/106596COMPOSITION COMPRISING DMPP AND PHOSPHONATE
WO 27.05.2022
Int.Class A01N 43/56
AHUMAN NECESSITIES
01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
NPRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
43Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds
48having rings with two nitrogen atoms as the only ring hetero atoms
561,2-Diazoles; Hydrogenated 1,2-diazoles
Appl.No PCT/EP2021/082260 Applicant WOCKLAB GMBH & CO. KG Inventor SCHMALZ, Dirk
The invention relates to a composition comprising (i) a specific pyrazole or an agriculturally acceptable salt thereof; (ii) a phosphonic acid or an agriculturally acceptable salt thereof; (iii) optionally, one or more carboxylic acids, agriculturally acceptable salts or anhydrides thereof; and (iv) optionally, one or more glycols. Compared to conventional compositions, the compositions according to the invention provide improved solubility of salts of pyrazoles such as 3,4 DMPP in aqueous solution. The solutions are stabilized against crystallization by lowering the crystallization point.
10.WO/2022/107166NOVEL CRYSTALLINE FORM OF TAFAMIDIS AND ITS PROCESS THEREOF
WO 27.05.2022
Int.Class A61K 31/423
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
41having five-membered rings with two or more ring hetero atoms, at least one of which is nitrogen, e.g. tetrazole
42Oxazoles
423condensed with carbocyclic rings
Appl.No PCT/IN2021/051080 Applicant NATCO PHARMA LIMITED Inventor BUDIDETI, Shankar, Reddy
The present invention relates to novel crystalline Forms of Tafamidis and process to prepare thereof. The present invention also relates to process of Tafamidis N-methyl-D-glucamine.